Type 2 & other diabetes

Electronic nose for detecting abnormal glucose metabolism in heart transplant recipients

Cardiovasc DiabetolPublished Diagnostic accuracy study

Authors' conclusion

Prediabetes or PTDM is common in HTR. eNose technology, especially when combined with clinical data, shows promise as a non-invasive screening tool with high specificity and PPV. This approach may reduce OGTT burden, pending further confirmation.

Study context

Population
Heart transplant recipients (HTR) >1 year post-transplant undergoing oral glucose tolerance test (OGTT), plus fasting HTR with known post-transplant diabetes mellitus (PTDM) as control group; 29% female, median age 56 years, median 7.8 years post-transplant
Participants
76 participants
Comparison
Electronic nose (eNose) alone vs eNose combined with clinical parameters, against OGTT
Outcome
Diagnostic accuracy of eNose for differentiating normal from abnormal glucose tolerance (prediabetes or PTDM)

Performance

As reported in the abstract

Normal vs abnormal glucose tolerance (prediabetes or PTDM)
Test or modelAUROCSensitivitySpecificityPPVNPVAccuracy
eNose alone0.70 (95% CI 0.57-0.83)69%67%87%40%68%
eNose + clinical parameters0.88 (95% CI 0.81-0.96)71%100%100%51%78%

AUROC

eNose alone0.70 (95% CI 0.57-0.83)
eNose + clinical parameters0.88 (95% CI 0.81-0.96)

Sensitivity

eNose alone69%
eNose + clinical parameters71%

Specificity

eNose alone67%
eNose + clinical parameters100%

PPV

eNose alone87%
eNose + clinical parameters100%

NPV

eNose alone40%
eNose + clinical parameters51%

Accuracy

eNose alone68%
eNose + clinical parameters78%

Further findings

Glucose tolerance status

Normal glucose tolerance
18
Prediabetes
33
PTDM (including 8 newly diagnosed)
25
Prediabetes or PTDM
76%

Original publication

Electronic nose for detecting abnormal glucose metabolism in heart transplant recipients. Cardiovasc Diabetol. Published 10 November 2025. doi:10.1186/s12933-025-02970-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.